Exchange: NASDAQ·Updated 07:37 PM EDT

SDGR News

News
all
press releases
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?
Recursion Pharmaceuticals is expanding its clinical pipeline across oncology and rare diseases, with REC-4881 and multiple programs offering potential growth catalysts.
Zacks
More News
"Schrodinger's Strait:" Why Hormuz Now Exists in a State of Permanent Uncertainty
"Schrodinger's Strait:" Why Hormuz Now Exists in a State of Permanent Uncertainty...
Yahoo! Finance: News
AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030
AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030 AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030 PR Newswire AUSTIN, Texas, Sept. 3, 2026 AUSTIN, Texas, Sept. 3, 2026 /PRNewswire/ -- Equity Insider News Commentary - Pharmaceutical research is being rebuilt...
PR Newswire
Schrdinger to Present at Morgan Stanley Global Healthcare Conference
Schrdinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The live presentation will take place on Monday, September 14, 2026 at 1:05 p.m. E.T. The live webcast can be accessed in the Investors...
Business Wire
When The Rule Of Law Fails
When The Rule Of Law Fails Authored by Madge Waggy, What follows emerges from seventeen months of examination into procedural collapses, constitutional erosions, and institutional betrayals that have accelerated beyond the capacity of conventional reportage to capture. Sources include...
Zero Hedge
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci
AI is reshaping drug discovery, with Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci advancing computational platforms and pipelines.
Zacks
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.
Zacks
Schrdinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrdinger, Inc. (Nasdaq: SDGR) today reported that on August 12, 2026, the company granted restricted stock units (RSUs) with respect to 3,315 shares of the companys common stock to two newly hired employees. These grants were made pursuant to the companys 2021 Inducement Equity Incentive Plan...
Business Wire
Schrodinger, Inc. (SDGR) Q2 Earnings and Revenues Top Estimates
Schrodinger (SDGR) delivered earnings and revenue surprises of +113.33% and +15.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Schrdinger Reports Second Quarter 2026 Financial Results
Schrdinger, Inc. (Nasdaq: SDGR) today announced financial results for the quarter ended June 30, 2026. We are very pleased with our second quarter results, delivering ACV of $29.6 million, which represents 27% growth. Our results reflect growing industry adoption of a predict-first approach to...
Business Wire

Advertisement|Remove ads.